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Abstract: Toxins that pass through the blood-brain barrier put neurons and glia in peril. The damage inflicted is usually  
a consequence of the ability of these toxic agents to induce free radical generation within cells but especially at the  
level of the mitochondria. The elevated production of oxygen and nitrogen-based radicals and related non-radical products 
leads to the oxidation of essential macromolecules including lipids, proteins and DNA. The resultant damage is referred  
to as oxidative and nitrosative stress and, when the molecular destruction is sufficiently severe, it causes apoptosis or  
necrosis of neurons and glia. Loss of brain cells compromises the functions of the central nervous system expressed as 
motor, sensory and cognitive deficits and psychological alterations. In this survey we summarize the publications related 
to the following neurotoxins and the protective actions of melatonin: aminolevulinic acid, cyanide, domoic acid, kainic 
acid, metals, methamphetamine, polychlorinated biphenyls, rotenone, toluene and 6-hydroxydopamine. Given the potent 
direct free radical scavenging activities of melatonin and its metabolites, their ability to indirectly stimulate antioxidative 
enzymes and their efficacy in reducing electron leakage from mitochondria, it would be expected that these molecules 
would protect the brain from oxidative and nitrosative molecular mutilation. The studies summarized in this review   
indicate that this is indeed the case, an action that is obviously assisted by the fact that melatonin readily crosses the blood 
brain barrier. 
Keywords: Aminolevulinic acid, cyanide, domoic acid, kainic acid, melatonin, metals, methamphetamine, polychlorinated 
biphenyls, rotenone, toluene, 6-hydroxydopamine.  
INTRODUCTION 
  The brain, including the spinal cord, is a very highly me-
tabolically active organ which, even at rest, utilizes an esti-
mated 20% of the total oxygen taken up by the lungs. This 
percentage increases substantially when the brain is active. 
Depriving the brain of its rich oxygen supply even for short 
intervals of a couple of minutes often has severe and irre-
versible detrimental morphological and physiological conse-
quences for both neurons and glia. Clearly then, the brain 
more so than any other tissue, is reliant on an uninterrupted 
oxygen-rich blood supply for its survival. 
  This high utilization of oxygen, however, comes at a 
heavy biological price. As important as oxygen is for the 
survival of neurons and glia, it also indirectly contributes to 
their destruction and death over time. The reason for this is 
that a small percentage (an estimated 1-4%) of the oxygen 
that enters cells is metabolized to derivatives that gradually 
erode and destroy essential molecules [30, 86, 148]. These 
destructive derivatives of oxygen are often referred to as free 
radicals (although some are not radicals per se) or reactive 
oxygen species (ROS). Some of the most noteworthy de-
structive oxygen metabolites include the superoxide anion 
radical (O2-), hydrogen peroxide (H2O2) and the hydroxyl 
radical (OH); this latter agent is especially toxic to cells and 
indiscriminately harms or destroys any molecule in the vicin-
ity of where the radical is generated [178]. O2-, albeit not  
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especially reactive, combines with nitric oxide (NO), to 
produce the peroxynitrite anion (ONOO
-), a non-radical 
product which is generally believed equivalent to the OH in 
terms of its ability to oxidize and destroy bystander mole-
cules. NO and ONOO
- are often referred to as reactive ni-
trogen species (RNS). 
  Cells must be equipped with means to quell the molecu-
lar damage meted out by ROS and RNS; if they have ineffi-
cient systems by which to protect themselves, the life of cells 
becomes dire. When intracellular molecules are mutilated by 
ROS/RNS, the cells become metabolically compromised 
eventually leading to cell death. When cells die and they are 
not replaced, such as occurs in most areas of the brain, the 
tissue falters and eventually organismal death is an unavoid-
able consequence.  
  To combat free radical (ROS/RNS) destruction, all life 
forms have evolved an array of means to either quench radi-
cal generation, to convert radicals to metabolically non-
destructive molecules, or to neutralize (scavenge) them im-
mediately after they are formed. This complex protective 
system which is designed to prevent radical-mediated organ 
malfunction, disease processes and aging is referred to as the 
antioxidative defensive system. 
  Remarkably, the brain is not especially effective at pro-
tecting itself from ROS/RNS. The reasons for this are sev-
eral-fold. Most importantly, as already mentioned, the CNS 
produces a disproportionately high number of ROS/RNS 
because of its use of seemingly more than its share of oxy-
gen, thereby generating more than the usual number of de-
structive ROS/RNS. The brain, seemingly unexpectedly, is 
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of the oxygen-based reactants to innocuous species. The 
CNS is highly enriched with polyunsaturated fatty acids 
which, more so than many other molecules, are readily oxi-
dized by toxic oxygen derivatives. Some areas of the brain 
contain large amounts of vitamin C (ascorbic acid); while 
vitamin C is an antioxidant capable of scavenging free radi-
cals, in the presence of free iron, it functions as a potent pro-
oxidant. This often occurs when there is hemorrhage in the 
CNS where escaped erythrocytes degenerate releasing he-
moglobin which then deteriorates leaving in its wake iron 
molecules. The blood-brain barrier, which is designed to 
protect the brain from toxins by limiting their diffusion into 
neurons and glia, also curtails the uptake of some protective 
agents, e.g., the antioxidant vitamin E, into the brain. This 
combination of features, or deficiencies, makes the brain 
highly susceptible to molecular destruction by ROS/RNS. 
  The current review is concerned with molecules, drugs or 
other agents which enter the brain and directly or indirectly 
generate ROS/RNS which destroy essential molecules lead-
ing to neuronal and glial loss and malfunction. Moreover, the 
survey reviews the ability of the endogenously-produced 
antioxidant, melatonin, to battle against free radical damage 
and to protect the brain from molecular mutilation which 
would inevitably lead to motor and sensory disability, psy-
chological disturbance and/or cognitive decline. 
MELATONIN AS AN ANTIOXIDANT 
  The processes by which melatonin quells molecular dam-
age resulting from oxygen derivatives are only briefly enu-
merated here since there are numerous reviews on this sub-
ject [4, 5, 90, 93, 189-191, 194, 196, 197, 244, 245]. The 
results summarized in these surveys should assure the reader 
of the high efficacy of melatonin and its derivatives in 
screening all cells, including those in the CNS, from molecu-
lar havoc. 
  N-acetyl-5-methoxytryptamine (melatonin), was discov-
ered as a potent antioxidant in 1993 [236]. Since then, mela-
tonin’s ability to protect all cells and organs from oxida-
tive/nitrosative damage has been confirmed in more than a 
thousand publications [17, 79, 128, 178, 197]. The in-
doleamine melatonin is produced in all animals from unicells 
to humans [71, 91, 92, 141, 248, 259] and also in plants [14, 
60, 94, 142, 159, 162, 172, 195, 240, 241]. Whereas mela-
tonin has many other functions in organisms, i.e., helping to 
synchronize circadian rhythms [6, 12, 102, 106, 112, 175], 
sleep promotion [12, 69, 105, 261, 274], immune stimulation 
[40, 82, 127, 146, 209, 210], blood pressure regulation [35, 
65, 200, 218, 225, 226,], seasonal reproductive regulation 
[44, 134, 187, 188, 201, 235], oncostatic [26-28, 51, 97, 110, 
120, 199, 214], antidepressive [113, 123, 140, 157, 192], 
etc., it seems to be unparalleled as an antioxidant. The ability 
of melatonin to protect cells from free radical injury extends 
from plants to humans [13, 41, 118, 179, 240, 241]. 
  Melatonin’s functional repertoire in terms of limiting 
molecular destruction by both oxygen and nitrogen-based 
radicals and associated metabolites is highly diverse. This 
indoleamine functions at all levels to aid in the ability of 
organisms to resist the onslaught of damage normally in-
flicted by radicals and radical-related products. Thus, mela-
tonin reduces free radical generation at the mitochondrial 
level in a process generally referred to as radical avoidance 
[88, 135, 147, 171], it stimulates antioxidative enzymes that 
convert highly toxic species to innocuous products [11, 18, 
43, 87, 168, 169, 208, 250], it promotes the synthesis of an-
other antioxidant, glutathione [252, 263], and it inhibits at 
least one enzyme, nitric oxide synthase, that normally pro-
duces free radicals, in this case NO [20, 26, 129, 181]. 
  Not only does melatonin carry out these functions to help 
cells avoid molecular damage, but it also directly neutralizes 
free radicals. In addition to melatonin itself, several of the 
metabolites that are formed when melatonin scavenges radi-
cals also participate in antioxidative defense by incapacitat-
ing toxic species [58, 63, 76, 89, 93, 143, 144, 149, 150, 176, 
232, 244, 275, 276] and by modulating the activities of en-
zymes that maintain the redox balance within cells [11, 168, 
169, 180, 213, 260, 270]. These functionally critical metabolites 
of melatonin include cyclic 3-hydroxymelatonin [137, 242], 
N1-acetyl-N2-formyl-5-methoxykynuramine [32, 114, 224, 
241, 243, 245], N1-acetyl-5-methoxykynuramine [81, 89, 124, 
206, 217], and perhaps others. Some of the antioxidative 
actions of melatonin, e.g., stimulation of antioxidative   
enzymes [18, 61, 168, 169, 202, 203, 208, 250] are likely 
receptor-mediated while others are receptor-independent, 
e.g., direct radical scavenging [108, 109, 171, 202, 236, 273]. 
  Via these collective mechanisms, melatonin appears to be 
an uncommonly efficient protector of molecules, subcellular 
organelles, cells, tissues and organisms from both harm as 
well as from death via apoptosis or necrosis due to a wide 
variety of toxic agents [66, 70, 119, 161, 167, 204, 223, 
272]. The subsequent paragraphs describe the results of stud-
ies where melatonin was used to protect neural tissue from 
toxic agents that damage the brain because of their ability to 
elevate the production of ROS and/or RNS. 
METHAMPHETAMINE 
  Methamphetamine (METH) is a drug of abuse that pro-
duces long-lasting neurotoxic effects on the CNS. Neuro-
chemically, this drug has potent inhibitory effects on tyrosine 
hydroxylase (TH) [116] and tryptophan hydroxylase (TPH) 
[100, 215]. These changes are associated with a drop in stri-
atal dopamine (DA) [100, 233] and serotonin (5-HT) [16, 
219] levels as well as a reduction in the transporters for both 
of these neurotransmitters [121, 207]. Free radicals are sus-
pected of being involved in these responses since transgenic 
mice that express human copper/zinc superoxide oxide dis-
mutase (CuZn SOD) exhibit an attenuated response to 
METH in terms of the reductions in neural DA and 5-HT 
concentrations [34, 55]. Indeed, O2- generation is consid-
ered a major culprit in the toxicity of METH [99].  
  Considering the likely involvement of ROS in the toxic-
ity of METH to neuronal monoaminergic systems, experi-
ments designed to attenuate the negative effects of METH 
using melatonin have been conducted. Unexpectedly, the 
first study performed claimed that melatonin (25 mg/kg), co-
administered with METH (15 mg//kg), actually exacerbated 
the neural deficits that normally occur after METH admini-
stration [75]. All subsequent experiments, however, have 
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tenuated METH damage to the CNS [9, 98, 101, 111, 117, 
234, 249, 264]. The doses of the respective drugs used by 
Gibb and colleagues [75] as well as the endpoints measured 
were similar as those employed by numerous other investiga-
tors, so an explanation as to why their findings so markedly 
differ is not readily apparent. The overwhelming consensus 
is that melatonin reduces or overcomes the neural toxicity of 
METH. 
  In the first study that revealed contrary findings to those 
reported by Gibb et al. [75], Hirata et al. [98] used melatonin 
doses ranging from 5-80 mg/kg that were intraperitoneally 
injected 30 minutes in advance of METH administration (4 x 
5 mg/kg) given at 2-hour intervals. Melatonin reduced the 
inhibitory effects of METH on both the DA and 5-HT trans-
porters in the striatum and nucleus accumbens of mice; these 
findings were documented using both biochemical and 
autoradiography methods. The obvious conclusion was that 
melatonin is protective against METH toxicity, at least in 
regard to the parameters measured and the brain areas exam-
ined.  
  The following three reports focused specifically on the 
ability of melatonin to modify the responses of neural DA 
metabolism to METH [9, 101, 104]. Using a variety of end-
points, it was shown that under all experimental situations 
tested melatonin reversed the effects of METH. These work-
ers speculated that melatonin’s beneficial actions in METH-
treated rodents may stem from its ability to reduce the hyper-
thermic action of the drug of abuse [9, 104]. The ability of 
melatonin to modify the body temperature-altering effect of 
METH is expected considering that melatonin by itself also 
reduces body temperature.  
  In the study of Imam et al. [101], ONOO
- was examined 
as a possible contributor to METH toxicity by measuring 
neural 3-nitrotyrosine (3-NT) formation. A single injection 
of METH produced a significant rise in 3-NT concentrations 
in the striatum signifying the involvement of ONOO
- in the 
destructive effects of this drug of abuse. Melatonin com-
pletely prevented the rise in 3-NT levels as well as reversing 
the depletion of striatal DA. The findings are consistent with 
the ONOO
-, an RNS and a strong oxidizing agent, being a 
participant in the damage to the brain inflicted by METH. 
Since melatonin has been shown to scavenge the highly toxic 
ONOO
- [25, 160, 278], it seems likely that the protective 
actions of melatonin against the neural damage inflicted by 
METH may involve its direct detoxification of the ONOO
-. 
  Since the immature brain is relatively deficient in an an-
tioxidative defense system, Kaewsuk and co-workers [111] 
anticipated that treating neonatal rats with the antioxidant 
melatonin would prevent at least some of the toxicity of 
METH in the newborn animals. METH (5-10 mg/kg) was 
given to rats on postnatal days 4 through 10. Each subcuta-
neous METH injection was preceded by a dose of 2 mg/kg 
melatonin. The drug of abuse reduced TH activity in the dor-
sal striatum, prefrontal cortex, nucleus accumbens and sub-
stantia nigra, while also lowering synaptophysin levels in the 
striatum and prefrontal cortex and growth-associated protein-
43 in the nucleus accumbens. Each of these changes was 
significantly attenuated in the neonatal mice that were given, 
in addition to METH, melatonin. The protective effects of 
melatonin in this study were presumed to be related to the 
direct scavenging and indirect antioxidant activity of mela-
tonin.  
  To further test the role of melatonin’s antioxidative po-
tential in mitigating the destructive effects of METH, in vitro 
studies using both cultured neuroblastoma and microglial 
cells were performed. Wisessmith et al. [264] and Suwan-
jang and colleagues [234] added METH to the medium in 
which human neuroblastoma cells (SH-SY5Y) were grow-
ing. The drug significantly reduced cell viability and TH 
activity while upregulating Bax, Bcl-2, cleaved caspase-3 
protein and calpain expression as well as reducing the   
endogenous calpain inhibitor, calpastatin. Each of these 
changes was abolished when METH-treated SH-SY5Y cells 
were also incubated with melatonin. The results of these 
studies document the induction of death signaling proteins 
by METH and further show that melatonin can reverse the 
effects of METH on these signaling pathways thereby pre-
serving neuronal viability. 
  While ROS and RNS are accepted as contributors to neu-
ronal death following METH administration, the effects of 
this drug on neuroinflammation have been less thoroughly 
tested. To examine this, aggressively proliferating immortal-
ized rat microglial (HAPI) cells were used [249]. As with 
neurons, the addition of METH reduced microglial cell vi-
ability in a concentration and time-dependent manner while 
upregulating the expression of inflammatory cytokines, inter-
leukin 1 (IL-1), interleukin-6 (IL-6) and tumor necrosis 
factor alpha (TNF-). Moreover, ROS and RNS generation 
was exaggerated as a result of METH administration; these 
were monitored using fluorescent probes. Melatonin abol-
ished all aspects of METH toxicity in this study. Clearly, the 
findings show that inflammatory cytokines as well as ROS 
and RNS may be involved in METH toxicity in the brain. 
That melatonin reversed these effects is consistent with its 
antioxidant and anti-inflammatory properties [24, 197, 209, 
254]. 
  Notwithstanding the one outlying report which claimed 
that melatonin actually enhanced the toxicity of METH [75], 
all subsequent investigations proved otherwise. Using multi-
ple endpoints, the published reports collectively support the 
idea that the antioxidant and anti-inflammatory actions of 
melatonin contribute to the ability of this indoleamine to 
mitigate the toxic neural effects of METH. 
AMINOLEVULINIC ACID 
  Acute intermittent porphyria (AIP) is associated with 
functional defects in both the central and peripheral nervous 
systems [271]. The pathophysiology that develops in this 
case is generally accepted as being secondary to the genera-
tion of ROS [59, 95]. AIP is characterized by elevated levels 
of -aminolevulinic acid (ALA), the agent likely responsible 
for the generation of oxygen-centered reactants in neural 
tissue [96]. Interestingly, patients with AIP also reportedly 
have depressed nocturnal levels of melatonin [184]. 
  Given the role of oxygen-based derivatives in the toxicity 
of ALA, Princ and co-workers [182] tested the efficacy of 
pharmacological concentrations of melatonin in reducing 
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ALA-mediated accumulation of lipid hydroperoxides was 
reduced, in a dose-dependent manner, by melatonin. These 
findings confirmed the likely involvement of free radicals in 
ALA-toxicity as well as showing that melatonin could poten-
tially be useful in overcoming the damaging effects of ALA. 
Whereas melatonin treatment required pharmacological lev-
els of melatonin, likewise the concentrations of ALA used to 
enhance the oxidation of lipids was also much higher than 
would ever be achieved in vivo. Thus, physiological concen-
trations of melatonin, or any oxidant, could not prevent the 
toxicity of such high levels of ALA. 
  These studies were extended by Carniero and Reiter [37] 
who showed that melatonin had a similar protective action 
against ALA-induced lipid peroxidation in the hippocampus 
and cerebral cortex just as it had in the cerebellum. In this 
study malondialdehyde and 4-hydroxyalkenals were meas-
ured as oxidative stress endpoints. This group also showed 
that in vivo as well as, the oxidation of cerebellar and hippo-
campal lipids resulting from ALA administration was attenu-
ated when melatonin was acutely administered before ALA 
was injected.  
  In vivo studies were also carried out by Princ and co-
workers [183] and they also reported melatonin’s ability to 
overcome ALA-induced neural lipid peroxidation. Moreover, 
melatonin treatment was found to preserve the activities of 
both porphobilinogen deaminase and -aminolevulinate de-
hydratase in the cerebral cortex. While the authors surmised 
that melatonin’s protective actions in part related to its abil-
ity to directly scavenge toxic reactants, they also felt that the 
indoleamine’s ability to protect against free radical damage 
was a result of its ability to stimulate antioxidative enzymes. 
Whereas they did not measure these activities, they based 
their supposition on earlier studies that showed that mela-
tonin is certainly capable of stimulating antioxidant enzyme 
activity [18, 168, 169]. 
6-HYDROXYDOPAMINE 
  The injection of the catecholaminergic neurotoxin, 6-
hydroxydopamine, directly into the substantia nigra of the 
midbrain leads to degeneration of the dopamine (DA)-
producing parikarya and subsequently the degeneration of 
the nigra-striatal pathway causing Parkinson-like signs in 
animals [54, 62]. Since the injection of the toxin is typically 
done unilaterally, the lesions develop only on one side with 
the resulting model being referred to as hemiparkinsonism 
[52, 228]. The neurodegenerative lesion is believed to in-
volve oxidative damage, mitochondrial malfunction, release 
of excitatory amino acids and a rise in intracytoplasmic free 
calcium [47, 163]. The neurons eventually die via apoptosis 
[31]. Given the involvement of oxidative damage and other 
downstream actions of 6-hydroxydopamine, it was antici-
pated that melatonin may ameliorate some of the effects of 
this drug. Both in vitro and in vivo studies have been carried 
out to test this possibility.  
  Mayo and co-workers [152] reported that the incubation 
of PC-12 neurons with 25 or 50 M 6-hydroxydopamine 
killed a large percentage of naïve PC-12 cells. Melatonin, 
added at a concentration of either 10
-7 to 10
-9 M highly sig-
nificantly reduced cell death mediated by the neurotoxin. 
Likewise, melatonin lowered DNA fragmentation resulting 
from 6-hydroxydopamine incubation in the PC-12 neurons. 
Besides functioning as a direct free radical scavenger in this 
study, melatonin also probably altered the PC-12 cell re-
sponse by adjusting the activities of two key antioxidative 
enzymes, MnSOD (manganese superoxide dismutase) and 
Cu/Zn SOD. Morphologically, melatonin preserved the ul-
trastructural morphology of PC-12 neurons cultured with 6-
hydroxydopamine further confirming the protective actions 
of melatonin against the neurotoxin [151].  
 The  in vitro protective actions of melatonin against 6-
hydroxydopamine toxicity was also documented in SK-N-
SH cells [46]. In these cells as well, melatonin preserved cell 
viability as revealed by the MTT (3- (4, 5-dimethylthiazol-2-
yl) -2, 5-diphenyl-tetrazolium bromide) assay. Moreover, the 
ability of melatonin to reduce neuronal cell death involved 
inhibition of the c-Jun-N terminal kinase signaling cascade. 
On the basis of these findings, the authors urged considera-
tion of the use of melatonin in clinical trials of free radical-
related neurodegenerative conditions. 
  In a series of two brief reports, a group of Korean scien-
tists [107, 115] were the first to examine melatonin’s ability 
to reduce the toxicity of 6-hydroxydopamine in vivo. In these 
studies, the unilateral Parkinsonism model was used. The 
neurotoxin caused rises in the level of malondialdehyde 
(142%) and reductions in TH (28%), DA (32%) and the do-
pamine metabolite, dihydroxyphenylacetic acid (50%) on the 
side of the lesion two weeks after the toxin had been 
stereotoxically injected. In the behavioral aspects of the 
study, melatonin also attenuated rotational asymmetry in-
duced by the injection of the dopamine receptor agonist, 
apomorphine. Melatonin also enhanced survival of the do-
paminergic cell bodies in the substantia nigra and the tyro-
sine-immunoreactive nerve terminals in the dorsolateral 
striatum as revealed by immunocytochemistry. 
  Similar observations were reported by Agular and co-
workers [7]. In this case the 6-hydroxydopamine was in-
jected into the striatum; the toxin caused significant de-
creases in DA, DOPAC (3, 4-dihydroxyphenyl acetic acid) 
and HVA (homovanillic acid). Melatonin, given in doses 
ranging from 2-25 mg/kg (given intraperitoneally for 7 days 
after 6-hydroxydopamine injection) caused a partial reversal 
(roughly 50%) of the losses in these neurotransmitters. As 
did Joo et al. [107] and Kim and colleagues [115], Agular et 
al. [7] also noted that melatonin prevented the abnormal ro-
tational behavior of the rats following an apomorphine injec-
tion. Finally, melatonin produced an upregulation of D1 re-
ceptor with a reduction in the Kd value.  
  It was also of interest to test the ability of melatonin to 
reduce the deficits in mitochondrial oxidative phosphoryla-
tion that are a result of unilateral 6-hydroxydopamine injec-
tions into the substantia nigra [56]. Using a novel BN-PAGE 
histochemical procedure, it was shown that mitochondrial 
complex I activity was significantly compromised in the 6-
hydroxydopamine-damaged neurons in the substantia nigra 
of rats. In rats implanted with subcutaneous mini-pumps that 
delivered a constant 50 + 7.5 g melatonin per hour, the sup-
pressed complex I activity was completely prevented. 6-
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complex IV activity with this drop also being reversed by the 
continuously-available melatonin.  
  Challenging the 6-hydroxydopamine-damaged rats with 
apomorphine caused the characteristic rotational behavior. 
There was a strong correlation in terms of the reduction in 
complex I activity and the severity of the rotational response. 
As in previously-reported studies, melatonin prevented the 
abnormal rotation, a response again correlated with the pres-
ervation of mitochondrial complex I activity. 
  That physiological levels of melatonin may be relevant to 
reducing 6-hydroxydopamine toxicity has also been investi-
gated [221]. In this study, melatonin was administered in the 
drinking fluid at a concentration of either 0.4 or 4.0 g/ml). 
The authors had calculated that these concentrations of mela-
tonin, when consumed by hemi-parkinson rats, would cause 
physiological levels of melatonin normally present in the 
blood and cerebrospinal fluid, respectively (cerebrospinal 
fluid, from the third ventricle, contains much higher concen-
trations than those measured in nighttime collected blood). 
The highest dose of melatonin significantly attenuated rota-
tional behavior compared to that observed in rats given vehi-
cle or the lower melatonin dose. When the brains of these 
animals were examined, those from rats given 4.0 g/ml 
drinking fluid exhibited normal TH immunoreactivity in the 
striatally-lesioned rats; in contrast, rats not given melatonin 
were essentially devoid of TH activity at the lesioned site. In 
comparison, when mRNA levels for TH were estimated there 
were no differences among the groups suggesting, according 
to the authors of the report [221], a spontaneous recovery of 
this transcript. 
  Two particularly novel publications have appeared in the 
last several years related to the issue of melatonin in relation 
to experimental Parkinsonism. In the first of these, C17.2 
neural stem cells (NSCs) were transplanted into the substan-
tia nigra of 6-hydroxydopamine-lesioned rats with or without 
melatonin co-administration [220]. In these animals, behav-
ioral studies documented that NSC transplantation, mela-
tonin administration, or a combination of both treatments 
significantly reduced abnormal rotational behavior. Moreo-
ver, each of the procedures reduced the loss of TH im-
munoreactivity in the striatum resulting from 6-
hydroxydopamine administration. The findings reported in 
this beautifully-illustrated paper document that combining 
NSC transplantation with melatonin treatment may improve 
outcome and, therefore, it could be a viable approach to use 
in the treatment of Parkinson disease. 
  L-DOPA (L-3, 4-dihydroxyphenylalanine) administration 
is used to restore DA levels in the brain of individuals diag-
nosed with Parkinson disease. The rise in neuronal DA 
causes the production of 6-hydroxydopamine [139], a mole-
cule, as summarized above, that has significant neural toxic-
ity. It is presumed that the neural toxin is a consequence of 
the high production of ROS at the site of the lesion in the 
substantia nigra. Given the presumed involvement of oxy-
gen-based radicals in vivo 6-hydroxydopamine production, it 
was surmised that melatonin would likely inhibit the produc-
tion of the neurotoxin. Using a ferrous-ascorbate-dopamine 
(FAD) hydroxyl radical generating system, it was found that 
melatonin prevented 6-hydroxydopamine formation from 
DA in vitro [29]. When FAD was infused into the medial 
forebrain bundle in the diencephalon of mice, a significant 
depletion of DA was recorded in the striatum. Treatment of 
mice with 30 mg/kg melatonin 30 minutes in advance of L-
DOPA administration reduced 6-hydroxydopamine produc-
tion in the brain and protected against DA depletion in the 
striatum. 
  Collectively, the studies summarized in this section of the 
review convincingly document the utility of melatonin   
in nullifying the toxicity of the neurotoxin, 6-hydro- 
xydopamine, and in preventing DA loss in neuronal cell bod-
ies in the pars compacta of the midbrain and in the nerve 
terminals in the striatum. This being the case, it seems rea-
sonable to suggest the use of melatonin as an experimental 
treatment of Parkinson disease. Its use for this purpose is 
emphasized by the essential lack of toxicity of this in-
doleamine and the ability to administer it via essentially any 
route.  
  Finally, given that L-DOPA is commonly used to treat 
Parkinson patients and the fact that it, while restoring DA 
levels, also induces 6-hydroxydopamine production in a 
process that involves free radicals, melatonin should be 
tested in combination with L-DOPA to determine if it would 
improve the longterm outcome of these patients. Addition-
ally, when NSCs are transplanted into the brain, the use of 
melatonin may prove worthwhile.  
ROTENONE 
  Rotenone, a pesticide, reproduces key behavioral symp-
toms and neuropathological features of Parkinson disease 
[23]. The changes include apomorphine-mediated rotational 
motor problems, degenerative changes in the nigrostriatal 
dopaminergic pathway, elevated oxidative stress and changes 
in the brain reminiscent of Lewy bodies; the intraneuronal 
inclusions that form are polyubiquitin and -synuclein-
positive [21, 22, 36]. Also, rotenone causes mitochondrial 
complex I inhibition leading to a selective depletion of DA 
from neurons of the substantia nigra [21] which obviously 
contributes to its toxicity [222]. 
  The first test of melatonin’s ability to inhibit rotenone 
toxicity used the fruit fly Drosophila melanogaster, as the 
experimental model [53]. This species is not an uncommon 
model in which to investigate drugs which influence neu-
rodegenerative diseases. Treatment of flies with rotenone 
exhibited characteristic locomotor impairments and examina-
tion of the brain clusters revealed a dramatic and selective 
loss of immunocytochemically-identified DA. When L-
DOPA was incorporated into the diet of the flies, the behav-
ioral deficits were alleviated but brain DA was not restored; 
this is similar to L-DOPA administration in the human. Add-
ing melatonin to the diet substantially alleviated both the 
behavioral abnormalities and, importantly, also prevented 
loss of DA neurons. The authors suggested the consideration 
of melatonin as a treatment for Parkinsonism in humans.  
  The intranigral infusion of rotenone caused the depletion 
of reduced glutathione (GSH) as well as changes in SOD and 
catalase in rats [216]. With the aid of a sensitive HPLC 
method, it was also found that rotenone enhanced OH gen-
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ured free radical generation, but also the changes in GSH and 
antioxidative enzymes induced by rotenone were prevented 
when pesticide treatment was coupled with melatonin. 
  When rotenone was infused subcutaneously for 14 days 
into rats, it produced Parkinson-like signs including lowered 
locomotor activity (hypokinesis), marked reduction in TH 
immunocytochemistry in the substantia nigra and striatum, 
-synuclein accumulation, downregulation of the dopamine 
transporter and upregulation of the D2 dopamine receptor 
[133]. These workers also examined the locus coeruleus and 
noted that rotenone depleted these neurons of norepineph-
rine. Melatonin (10 mg/kg/day) administration prevented the 
changes observed in the nigrostriatal system and -synuclein 
aggregation; melatonin did not, however, alleviate the obvi-
ous hypokinesis seen in the rotenone-treated rats. Finally, 
melatonin also reduced the downregulation of the dopamine 
transporter and the upregulation of the D2 receptor. On the 
basis of the outcome of this thorough series of investigations, 
it was concluded that rotenone toxicity is at least partially 
related to free radical damage and that melatonin may be 
useful to counteract some of the degenerative changes asso-
ciated with Parkinsonism [133]. 
  There is one study in which the findings run contrary to 
those reported in the previous paragraphs. Thus, when mela-
tonin (total of 20 mg/kg daily; 10 mg/kg X 2 daily) was ad-
ministered to rotenone-treated male Lewis rats (a strain not 
used in other reports that showed melatonin protected against 
rotenone), it failed to reverse the depletion of DA and its 
metabolites (DOPAC and HVA) in the striatum induced by 
the pesticide [246]. Indeed, melatonin actually further low-
ered the striatal depletion of these constituents caused by 
rotenone. Likewise, the authors reported that melatonin fur-
ther diminished striatal and nigral TH immunoreactivities. 
Why the findings reported differ so widely from a number of 
other studies which revealed that melatonin reverses the sup-
pressive effect of rotenone and other neurotoxins on neural 
DA levels was not readily apparent to the authors of the re-
port. They did, however, make one curious observation that 
could have accounted for the unusual responses that they 
observed in the rotenone-injected rats. Thus, in control ani-
mals given melatonin only, striatal DA levels were signifi-
cantly elevated over those in all other groups; whether this 
was also true in the substantia nigra was not reported. Ac-
cording to the authors, a rise in striatal DA may have poten-
tiated the effects of rotenone-induced complex I inhibition 
and thereby elevated the degree of oxidative stress. Since 
Tapais et al. [246] did not include any measures of free radi-
cal damage in their studies, they proposed that this should be 
a goal of further mechanistic studies. 
  In summary, the interaction of melatonin and rotenone in 
terms of DA metabolism, as assessed at the level of the stria-
tum and substantia nigra, requires further investigation. 
While the majority of studies found melatonin to be protec-
tive against the neurotoxicity of rotenone, the final report 
discussed in the previous paragraph noted otherwise. Moreo-
ver, there is no ready explanation for the different outcomes 
of the summarized publications. This issue requires resolu-
tion with additional experimentation since the findings 
could, theoretically at least, have implications for other drugs 
that also disturb the dopaminergic system. 
  Another frequently used drug to induce Parkinson-like 
signs in experimental animals is 1-methyl-4-phenyl-1, 2, 3, 
6-tetrahydropyridine (MPTP). This subject is not covered in 
the current review since there are a variety of recent publica-
tions and reviews on this subject [3, 45, 48, 153, 209]. Like-
wise, with the exception of the findings related to aluminum 
administration, the ability of melatonin to resist the devel-
opment of Alzheimer disease signs following drug admini-
stration is not discussed in this review since Alzheimer dis-
ease is considered in another chapter in this volume and 
there is extensive literature published on this subject [164, 
170, 209]. 
METALS 
  The toxicity of metals is often explained on the basis of 
their ability to cause the generation of oxygen and nitrogen-
based reactants [132, 253]. Iron (Fe), chromium (Cr), alumi-
num (Al), copper (Cu), vanadium (V) and cobalt (Co) un-
dergo redox cycling reactions thereby permitting massive 
free radical production. Other metals including mercury 
(Hg), cadmium (Cd) and nickel (Ni) have the ability to de-
plete the important endogenous antioxidant glutathione, and 
also to bind to sulfhydryl groups on proteins. Several of 
these metals participate in the Fenton reaction which pro-
duces the highly reactive OH. In general, antioxidants (both 
enzymatic and non-enzymatic) combat the deleterious ac-
tions of metals in the central nervous system, provided they 
are capable of crossing the blood-brain barrier. 
  Al has been implicated in the etiology of Alzheimer dis-
ease, although its contribution to this debilitating neurode-
generative condition still remains unresolved [122, 155]. 
Given the potential association of Al with Alzheimer demen-
tia, molecules or antioxidants that limit its toxicity in the 
central nervous system are of obvious interest. 
  That melatonin may be capable of reducing oxidative 
damage to the central nervous system in Al-treated rodents 
has been examined in a number of publications. Accord-
ingly, Esparza et al. [68] intraperitoneally injected Al into 
male rats with or without concurrent melatonin administra-
tion. At necropsy, the cerebral cortex, hippocampus and 
cerebellum were examined for their Al content; Al was in 
especially high levels in the cerebellum in the animals that 
received the metal. While melatonin did not change Al up-
take by the brain, the results of this study clearly documented 
that Al is a pro-oxidant in the brain while melatonin reduced 
the molecular damage resulting from Al toxicity. The   
endpoints in this initial study were indirect measures of   
oxidative stress and included activities of glutathione-
metabolizing enzymes and the neural levels of lipid peroxi-
dation. The same group showed in two subsequent reports 
that the mRNAs for antioxidant enzymes were elevated in 
the cortex and cerebellum [67] and the hippocampus [80] of 
Al-treated rats that had also received melatonin. The daily (5 
days a week) doses of Al and melatonin in this 11-week 
study were 7 mg/kg and 10 mg/kg, respectively. Since mela-
tonin did not influence the neural uptake of Al, it was pre-
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scavenging activity and its ability to stimulate antioxidative 
enzymes. Despite the benefits of melatonin in terms of pro-
moting antioxidative enzyme mRNA expression and activity 
levels in Al-treated animals [72-74], the indoleamine did not 
change the behavioral outcomes of transgenic mice (Tg2576; 
they express elevated levels of amyloid--precursor protein) 
in the open field and Morris water maze tests [74]. 
  While this series of studies, all from the same laboratory, 
related to the apparent protective actions of melatonin 
against neural damage induced by Al administration to ro-
dents suggests some benefits of administration of the in-
doleamine, there are only sparse data documenting that mela-
tonin actually reduced the degree of neural oxidative damage 
that may have resulted from Al toxicity. This question 
should be addressed in any subsequent investigations related 
to the interactions of Al and melatonin in the central nervous 
system. In a related study in a non-rodent species, melatonin 
reduced the neural toxicity of chronic Al (as aluminum chlo-
ride; 20 mg/l via the drinking fluid) administration to rabbits 
[2]. Neural malondialdehyde and 6-hydroxyalkenal levels, 
indicative of lipid peroxidation, were elevated as a result of 
Al consumption and were reduced in the melatonin-treated 
rabbits. Neuropathological examination of the brain also 
suggested a protective action of melatonin against Al neuro-
toxicity.  
  Co, a positively charged transition metal, has been found 
to be elevated in the postmortem brain of Alzheimer’s dis-
ease patients [247] with a particular high concentration in the 
nucleus of neurons [262]. When SHSY5Y neuroblastoma 
cells were incubated in serum-free medium containing 300 
M CoCl2, the metal induced cytotoxicity and cell death as 
well as inducing the release of amyloid- [165]. When 1 M 
melatonin was also added to the incubation medium, the 
deleterious actions were reversed. Whether melatonin would 
protect against the neural toxicity of Co in vivo has not been 
tested.  
  Fe is a transition metal that is commonly implicated as 
contributing to oxidative damage due to its participation in 
the Fenton reaction which results in the generation of the 
highly reactive OH. Fortunately, most Fe in vivo is bound 
and, therefore, cannot participate in the Fenton reaction. Al-
though there are limited in vivo studies on the efficacy of 
melatonin in protecting against free Fe toxicity, in vitro it 
readily reduces molecular damage in cells resulting from 
their exposure to Fenton reagents [136]. In this capacity, 
melatonin was more effective in protecting against DNA 
damage than xanthurenic acid, resveratrol (3, 4’, 5-trihydro-
trans-stilbene), EGCG [(-)-epigallocatechin-3-gallate], vitamin 
C or alpha-lipoic acid. A hepatic metabolite, 6-hydro- 
xymelatonin, also was shown to reduce Fe toxicity after the 
infusion of ferrous citrate directly into the hippocampus of 
rats; the metabolite was, however, less potent than melatonin 
itself in reducing hippocampal lipid peroxidation and neural 
damage [138].  
  The toxicity of the heavy metal, lead (Pb), is well docu-
mented [1]. The nervous system, among many organs, is 
negatively influenced by Pb ingestion [211, 257, 277]. The 
negative neural consequences of this heavy metal are gener-
ally accepted as involving disturbances in the mitochondria 
which causes the generation of excessive numbers of free 
radicals [103, 258]. Armed with this information, El-Sokkary 
and colleagues [64] treated rats with either Pb or Pb plus 
melatonin to determine whether the indoleamine would mod-
ify the degree of oxidative damage in the brain of rats. As 
anticipated, rats injected subcutaneously with lead acetate for 
21 days had high levels of malondialdehyde and 4-hydro- 
xyalkenals in the brain. Additionally, reduced glutathione 
levels and diminished SOD activity were also apparent.   
Giving melatonin injections in advance of lead acetate essen-
tially reversed all the oxidative damage that accompanied the 
neural toxicity of Pb. 
  Hg is frequently ingested in the diet and is becoming an 
increasingly common environmental contaminant. When rats 
were treated with mercuric chloride (4 mg/kg), it induced a 
variety of changes in the cerebral cortex, cerebellum and 
brain stem (medulla) [186]. The changes were estimated to 
be most severe in the cerebral cortex. Co-administration of 
melatonin (5 mg/kg) attenuated the neural changes. While 
these findings suggest melatonin may be protective of the 
brain against Hg toxicity, a solid conclusion to this effect 
should not be based on the results of this single study.  
  Using absorptive cathode stripping voltammetry, two 
reports [124, 131] tested whether melatonin binds metals 
thereby potentially altering how they impact neural tissue. 
The studies revealed that melatonin does interact with Cu, 
Cd, Fe
3+, Pb, Zn and Al. Due to these chelation reactions, 
melatonin could retard the Fenton reaction and thereby pre-
vent OH generation. Alternatively, attenuated endogenous 
melatonin levels could predispose to the buildup of toxic 
metals which would likely contribute to molecular damage in 
the brain and elsewhere.  
TOLUENE 
  Toluene vapor inhalation causes adverse effects in the 
central nervous system with associated behavioral abnor-
malities [15, 125]. When rats were chronically exposed to 
toluene, elevated levels of lipid peroxidation were also 
measured in the cerebral cortex, hippocampus and cerebel-
lum; the administration of melatonin, however, counteracted 
the effects of toluene and returned lipid oxidation to essen-
tially control levels [19]. Subsequently, Pascual and associ-
ates [173] conducted a thorough investigation related to the 
potential protective actions of melatonin in protecting den-
drite development in young rats that inhaled toluene vapors 
(5,000-6,000 ppm for 10 minutes daily for 12 days). This 
exposure strategy was designed to simulate the situation of 
toluene abuse in humans where individuals are exposed to 
high concentrations of vapor for repeated short intervals. 
When the brains were collected and analyzed 7 days after the 
last toluene inhalation, there was a marked suppression of 
dendritic outgrowth in layer II and III pyramidal neurons in 
the cerebral cortex; also of the dendrites that did grow the 
number of branches was significantly attenuated. These find-
ings documented that subchronic toluene inhalation in young 
rats had a dramatic effect on basal dendrite development and 
branching in the frontal, parietal and occipital pyramidal 
neurons. When melatonin was given at a dose of 5 mg/kg, it 
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protective, likely via its antioxidative mechanisms, against 
toluene toxicity. 
POLYCHLORINATED BIPHENYLS 
  The neurotoxic effects of polychlorinated biphenyls 
(PBCs) are a consequence of their ability to produce free 
radicals. The proteins embedded in membranes which con-
trol ionic gradients across both plasma and organellar mem-
branes are especially easily damaged when oxidized by 
PBCs. When rats were treated with PBC (Aroclor 1254; 2 
mg/kg daily for 30 days) neural levels of lipid peroxidation 
products along with concentrations of OH and H2O2  
were elevated. Conversely, GSH concentrations as well   
as the activities of a variety of enzymes (Na
+K
+ATPase, 
Ca
2+ATPase, Mg 
2+ATPase and acetylcholinesterase) were 
diminished [255]. Giving melatonin (either 5 or 10 mg/kg 
daily) in combination with the PCB reversed the effects of 
PBC. In a follow-up study where Aroclor 1254 was used to 
induce neuronal damage and suppress CuZnSOD and GPx-4 
mRNA expression, melatonin again relieved the effects of 
the PCB [256]. In this study, the benefits of melatonin 
against PCB neurotoxicity were seen in the cerebral cortex, 
the hippocampus and cerebellum. In both studies, the protec-
tive actions of melatonin were attributed to its antioxidative 
actions. 
KAINIC ACID 
  Kainic acid is a neurotoxin isolated from sea weed. When 
injected into animals it mimics the action of the excitatory 
amino acid neurotransmitter, glutamate [166]. Kainic acid 
produces acute and subacute epileptiform activity that can 
last for days. Ultimately, it causes widespread irreversible 
neuropathological changes that involve both neurons and glia 
[231]. Kainic acid binds to and activates a subtype of 
ionotropic glutamate receptor. In addition to inducing   
brain lesions directly, probably via  processes involving   
free radicals, kainic acid also provokes the discharge of   
potentially neurotoxic quantities of glutamate from nerve 
endings [54]. 
  Given that free radicals are likely involved in the neu-
rodestructive processes of kainic acid, soon after melatonin 
was discovered as a free radical scavenger, it was tested for 
its antiexcitatory efficacy. In the initial study, when cerebel-
lar granule neurons were incubated with kainic acid the   
resultant destruction of the neurons was obvious; the toxic-
ity, however, was prevented when melatonin had been added 
to the incubation medium [83]. In this study the authors 
documented that melatonin did not directly inhibit the action 
of kainic acid on glutamate receptors. 
  In vivo as well, melatonin reduced the ability of kainic 
acid to kill neurons in both the cerebellum and in the hippo-
campus [85, 238]. Moreover, melatonin reduced the associ-
ated neural lipid peroxidation as well as preventing the death 
of the majority of the rats that received kainic acid [84, 85, 
238]. Not only pharmacological amounts of melatonin, but 
likewise pinealectomy, which only depletes physiological 
concentrations, enhances the severity of neural damage in-
duced by kainate [145]. The authors of these reports were 
convinced that the beneficial effects of melatonin against 
neurotoxicity of kainic acid were due to melatonin’s ability 
to readily enter the brain and scavenge free radicals and 
stimulate antioxidative enzyme activities in the affected neu-
rons. The figures in the Tan et al. [238] report illustrate the 
marked protective action that melatonin has on hippocampal 
pyramidal neurons that are normally damaged by kainic acid. 
The ability of melatonin to shield these neurons from free 
radical damage is of particular interest since pyramidal neu-
rons are also lost, via mechanisms involving oxidative and 
nitrosative stress, in a variety of neurodegenerative diseases. 
  In cerebellar granule neurons, Dabbeni-Sala et al. [57] 
found that kainic acid increased mitochondrial free radical 
generation (identified with 2’, 7’-dichlorofluorescein) and 
impaired the function of complex II of the respiratory chain. 
Moreover, kainate promoted the activity of nitric oxide syn-
thase thereby elevating the production of NO and ulti-
mately of ONOO
-. In this series of in vitro studies, melatonin 
proved effective in combating both the oxidative and nitrosa-
tive stress associated with the exposure of cerebellar granule 
neurons to kainic acid. 
  Follow-up studies have consistently confirmed the effi-
cacy of melatonin in reducing free radical-mediated toxicity 
due to kainate administration to animals. Confirmation of 
mitochondrial level of action of melatonin during excitotox-
icity was provided by the observations that melatonin also 
prevented mitochondrial DNA damage [156, 267] while also 
reducing seizures that often accompany kainic acid admini-
stration [267]. Neuronal death that occurs in these situations 
is presumably the result of apoptosis. 
  Chuang and co-workers [49] provided direct evidence 
that in fact apoptosis was the process that leads to cellular 
implosion after kainate is given. Three days following the 
intrastriatal injection of kainic acid, these workers noted the 
dramatic cytotoxic action of the drug along with elevated 
Bcl-2 immunoreactivity in TUNEL-positive cells. Although 
detectable, less severe damage was seen in the ipsilateral 
substantia nigra. Melatonin reduced Bcl-2 expression and 
preserved neuronal viability (reduced the number of 
TUNEL-positive neurons). Similar effects of melatonin on 
Bcl-2 expression in kainic acid-treated rat hippocampal neu-
rons were reported by Yalcin and colleagues [265]. In addi-
tion to reducing hippocampal neuronal death due to its direct 
scavenging activity, melatonin may be protective since it 
stimulates the antioxidative enzymes, SOD and catalase, in 
these cells as well [8]. 
  Chung and Han [50] surmised that the toxicity of kainic 
acid in relation to selective neuronal loss in the hippocampus 
may involve activation of microglia. Thus, besides enhanc-
ing the release of excessive amounts of the excitatory amino 
acid neurotransmitter, glutamate, which leads to damage of 
the post synaptic neuron, kainic acid may also activate mi-
croglial cells and the production of ROS which would further 
exaggerate the neuronal damage. Also, since free radicals 
were presumed to be involved and given the documented 
antioxidant properties of melatonin, they also examined the 
ability of this indoleamine to abrogate radical damage, neu-
ron death and microglial activation.  
  When rats were injected with a single 10 mg/kg kainate, 
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DNA damage, an increased number of TUNEL-positive neu-
rons, reduced cell viability and elevated numbers of micro-
glia (identified by means of isolectin-B4 histochemistry) and 
astroglial responses (identified by glial fibrillary acidic pro-
tein immunocytochemistry); these changes were most 
prominent in the pyramidal cells of the hippocampus and in 
the surrounding neuropil. An accumulative dose of 10 mg/kg 
melatonin (given as 2.5 mg/kg X 4) to kainic acid-treated 
rats significantly lowered the resulting pyramidal cell death, 
lipid and DNA damage, microglial activation and to a lesser 
degree astrogliosis. TUNEL-positive neurons were espe-
cially prominent in the CA1 and CA3 pyramidal neurons 
after kainate. 
  The authors [50] feel that melatonin’s ability to protect 
against the toxicity of kainic acid includes its direct effects 
within neurons as well as reducing the reactive gliosis which 
is believed to generate free radicals which also presumably 
contributed to neuronal damage. Additionally, although not 
specifically investigated in this study, they feel the anti-
inflammatory effects of melatonin may have contributed to 
its neuroprotective efficacy [39, 209].  
  The results of a subsequent publication also implied that 
glial elements may be involved in kainic acid-mediated dam-
age in the hippocampus and melatonin’s protective actions 
may likewise involve glial cells [126]. As with the earlier 
publication, kainate, injected directly into the cerebroventri-
cle, was found to activate both astroglial cells as indicated by 
the upregulation of GNDF (glial cell line-derived neurotro-
phic factor) and microglial elements (evaluated with micro-
glial markers, OX-2); these responses were significantly at-
tenuated when melatonin was also administered.  
  In addition to examining glial responses associated with 
kainate administration, Lee and colleagues [126] also evalu-
ated pyramidal cell death (TUNEL assay), total and phos-
phorylated Akt and iNOS expression. Melatonin reduced 
CA3 neuron cell death, upregulated Akt and downregulated 
iNOS, all of which contributed to preservation of hippocam-
pal pyramidal neurons. This beautifully written paper should 
be consulted for the purpose of visualizing the preserved 
CA3 neurons, the activation of the glial elements and the 
upregulation of Akt by melatonin. 
  As illustrated in studies summarized in this section, mela-
tonin is highly effective in overcoming the toxicity of kainic 
acid at the level of the hippocampus. The findings have clear 
implications for several types of seizures which culminate in 
the massive discharge of glutamate from mossy fibers onto 
hippocampal pyramidal neurons often resulting in the death 
of these cells. The studies summarized here indicate that 
melatonin, due to its ability to attenuate kainic acid (a gluta-
mate analog) toxicity as well as its efficacy in inhibiting sei-
zures themselves [154, 158, 174, 229], may be useful as a 
treatment for epilepsy. The evidence to date strongly sup-
ports this conclusion. 
DOMOIC ACID 
  Domoic acid is a kainate receptor which has potent neu-
rotoxic activity. When intravenously administered into rats, 
it induced neural degeneration, glial activation and elevated 
iNOS activity in the hippocampus [10]. As with kainate, 
pyramidal neurons in the CA1 and CA3 subfields as well as 
those of the dentate hilus were severely damaged (based on 
Nissl staining). Immunoreactive astrogliosis was identified 
using GFAP (glial fibrillary acid protein) while OX-2 de-
lineated a large number of microglial cells. Domoic acid-
mediated neuronal death, reactive gliosis and iNOS protein 
expression were all reduced to control levels when domoic 
acid-treated rats also received melatonin. 
  One additional study also investigated the ability of 
melatonin to abrogate the death of cerebellar granule cells 
following domoic acid administration to mice [78]. The kai-
nic acid analog caused elevated levels of intracellular and 
mitochondrial calcium levels, increased mitochondrial oxida-
tive stress, changes in mitochondrial membrane potential, 
cytochrome c release, caspase 3 activation and degradation 
of poly (ADP-ribose) polymerase which culminated in gran-
ule cell apoptosis. Domoic acid was incapable of inducing 
these changes in mice co-treated with melatonin. Since the 
toxicity of domoic acid likely involves exaggerated free 
radical generation resulting in elevated oxidative and nitrosa-
tive stress [42], melatonin’s function as an antioxidant is 
presumed to be involved in the mechanisms by which it re-
duced the toxicity of domoic acid. 
CYANIDE 
  A cyanide is a compound that contains a triple bond be-
tween a carbon atom and a nitrogen atom. Cyanides that re-
lease the cyanide ion are highly toxic. Cyanide toxicity stems 
from the ability of the ion to inhibit cytochrome c oxidase in 
the mitochondrial respiratory chain. 
  The subcutaneous injection of potassium cyanide (6, 8, or 
9 mg/kg) dose-dependently induced severe tonic seizures in 
mice and elevated levels of products of lipid peroxidation in 
the brain of these animals; this latter observation suggests 
that the interaction of cyanide with oxidative phosphoryla-
tion generates increased numbers of free radicals, likely via 
elevating electron leakage from the respiratory complexes. 
Yamamoto and Tang [266, 268, 269] found that not only did 
melatonin reduce cyanide-induced lipid breakdown in the 
brain but it also limited the number of seizures the mice ex-
perienced and reduced the death rate of animals that fol-
lowed their exposure to the lethal agent. In a combination of 
in vitro and in vivo studies, this group also found that mela-
tonin limited cyanide-mediated damage to brain mitochon-
drial DNA [267]. Treating mice with potassium cyanide was 
also found to induce neuronal death in the substantia nigra of 
mice with this response likewise being attenuated by giving 
melatonin [47]. 
PERSPECTIVES AND CONCLUSIONS 
  Melatonin is an uncommonly functionally diverse mole-
cule and a highly effective direct free radical scavenger and 
indirect antioxidant [237, 239]. Additionally, it readily 
crosses the blood-brain barrier and permeates into every cell, 
i.e., neurons and glia. These observations, coupled with its 
exceptionally high levels in the third ventricular cerebrospi-
nal fluid [130, 227, 251], are consistent with the likelihood 
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the brain against the onslaught of radicals that are suffi-
ciently reactive to mutilate essential molecules in both neu-
rons and glia. Such protection is critical given the high utili-
zation of molecular oxygen by cells in the central nervous 
system.  
  This review summarizes some of the agents that normally 
inflict damage at the neural level and reviews the studies 
documenting the ability of melatonin to shield the brain from 
oxidative and nitrosative damage. Almost uniformly, al-
though there are exceptions as mentioned herein, melatonin 
demonstrated its efficacy in safeguarding neurons and glia 
from the persistent molecular disfiguring that would other-
wise occur. The problem with loss of neurons is that, again 
with few exceptions [77], once these cells undergo either 
apoptosis or necrosis, they are not replaced. Interestingly, 
neuron precursors in the brain in those select areas where 
cellular proliferation does occur, are also stimulated by mela-
tonin [114, 143, 185, 205, 230]. 
  One deficiency with the majority of studies summarized 
in this review is the absence of tests involving the potential 
involvement of either membrane receptors and nuclear or 
cytosolic binding sites in the observed protective actions of 
melatonin in the central nervous system [202]. Whereas the 
direct free radical scavenging functions of melatonin require 
no receptor [88, 236], those related to the stimulation of an-
tioxidative enzymes or enhanced glutathione synthesis may 
involve one or more of the receptors mentioned above [250]. 
Moreover, there may be yet unidentified functions of mela-
tonin and its metabolites that contribute to the ability of these 
molecules to render ROS/RNS inept in mediating molecular 
damage that involve the receptors or binding sites that have 
been identified. 
  Another issue that has not been resolved is whether en-
dogenous, physiological concentrations of melatonin are 
sufficient to protect tissues, including the brain, from the 
day-to-day attacks by oxygen and nitrogen-based reactants. 
In the reports reviewed in this survey, melatonin was usually 
given in pharmacological concentrations. Of course, this was 
necessary (and would be for any antioxidant) because of the 
very large increases in free radical generation resulting from 
the injection of highly toxic agents. One cannot expect 
physiological levels of melatonin, or any radical scavenger, 
to protect against pharmacological levels of free radicals. If, 
in fact, this could be accomplished by the amounts of scav-
engers that normally exist within cells, no oxidative damage 
would ever occur. Since molecular damage accumulates 
throughout the life time of virtually all organisms, it is obvi-
ous that the radical scavengers (and there are many) nor-
mally present within cells are inadequate to stave off all 
radical attacks. 
  Finally, given that endogenous melatonin levels fall sub-
stantially with age, at least based on blood and pineal levels 
of the indoleamine [193, 198, 212], then it could be assumed 
that the loss of this potent antioxidant may contribute to   
the development of diseases that involve free radical damage 
as well as to aging itself [33, 38, 177]. It also suggests that 
exposure to the toxins mentioned in this report would be 
more serious in older individuals. Whereas this has yet to be 
experimentally considered, it is something that should be 
examined. 
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